(firstQuint)Enzalutamide & Dutasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.

.

 The primary objective of this study is to determine the effect of enzalutamide and dutasteride on the time to prostatic-specific antigen progression in patients aged 65 or older receiving this combination as first line treatment for systemic prostate cancer.

 To determine the safety and toxicities of the study drug combination.

 To determine the time to prostatic-specific antigen nadir from the start of study treatment and to evaluate the absolute prostatic-specific antigen nadir as a result of the study drug combination.

 Enzalutamide & Dutasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.

@highlight

Determine the effect of enzalutamide and dutasteride on the time to prostatic-specific antigen level increase in patients age 65 or older.

